Combining immunostimulants in adjuvants can improve the quality of the immune response to vaccines. Here, we report a unique mechanism of molecular and cellular synergy between a TLR4 ligand, 3-O-desacyl-4’-monophosphoryl lipid A (MPL), and a saponin, QS-21, the constituents of the Adjuva...
This human LN explant model is a valuable tool for studying the mechanism of action of adjuvants in humans and for screening new formulations to streamline vaccine development.Vicki V. StylianouKirstie M. BertramVan Anh VoElizabeth B. Dunn...
As in the liver infection experiments, all mice received a constant amount of adjuvant (10 fold diluted original AS01E adjuvant dose, representing 2.5 µg of the TLR4 ligand 3-O-desacyl-4’-monophosphoryl lipid A (MPL), and 2.5 µg of the QS-21 saponin). Seven positive ...
The RTS, S antigen has a highly recurrent structure, which is why immunization is believed to aid in the defense mechanism by producing anti-CSP antibodies and T cells [42]. The RTS, S vaccine was exposed to a wide range of adjuvants by GSK researchers, almost all of which were found ...
Aim: The review was aimed to assess the safety of the candidate malaria vaccine RTS,S with AS01 and AS02 adjuvants using data from Phase I–III randomized controlled clinical trials (RCTs). Methods: This systematic review was conducted based on PRISMA 2020. Regardless of time of publication...
Together with the TLR4-ligand MPL, QS-21 is part of the Adjuvant System AS01, a key component of the malaria and zoster candidate vaccines that display demonstrated clinical efficacy. However, the mechanism of action of QS-21 in this liposomal formulation is poorly understood. Upon intra-...
significantly higher efficacy than the 012M regimen, which is consistent with a link between lower OPA and protection. It is possible that phagocytosis mediated by CSP-specific antibodies may not contribute to protection, but instead constitute an immune escape mechanism, similar to that shown in ...
Together with the TLR4-ligand MPL, QS-21 is part of the Adjuvant System AS01, a key component of the malaria and zoster candidate vaccines that display demonstrated clinical efficacy. However, the mechanism of action of QS-21 in this liposomal formulation is poorly understood. Upon intra-...
Together with the TLR4-ligand MPL, QS-21 is part of the Adjuvant System AS01, a key component of the malaria and zoster candidate vaccines that display demonstrated clinical efficacy. However, the mechanism of action of QS-21 in this liposomal formulation is poorly understood. Upon intra-...